Bioversys AG (BIOV) - Total Liabilities
Based on the latest financial reports, Bioversys AG (BIOV) has total liabilities worth CHF30.82 Million CHF (≈ $38.97 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BIOV financial resilience to evaluate the company's liquid asset resilience ratio.
Bioversys AG - Total Liabilities Trend (2024–2025)
This chart illustrates how Bioversys AG's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Bioversys AG (BIOV) total assets.
Bioversys AG Competitors by Total Liabilities
The table below lists competitors of Bioversys AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Liberty Global PLC Class B
NASDAQ:LBTYB
|
USA | $12.43 Billion |
|
PIE Industrial Bhd
KLSE:7095
|
Malaysia | RM165.48 Million |
|
CHOROKBAEM COMPANY Co. Ltd
KQ:052300
|
Korea | ₩80.01 Billion |
|
Epsilon Energy Ltd
NASDAQ:EPSN
|
USA | $106.53 Million |
|
WW International, Inc. Common Stock
NASDAQ:WW
|
USA | $645.76 Million |
|
Wah Hong Industrial
TWO:8240
|
Taiwan | NT$3.07 Billion |
|
Mieco Chipboard Bhd
KLSE:5001
|
Malaysia | RM268.31 Million |
|
AVerMedia Technologies Inc
TW:2417
|
Taiwan | NT$1.82 Billion |
Liability Composition Analysis (2024–2025)
This chart breaks down Bioversys AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Bioversys AG to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioversys AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioversys AG (2024–2025)
The table below shows the annual total liabilities of Bioversys AG from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF30.82 Million ≈ $38.97 Million |
+26.99% |
| 2024-12-31 | CHF24.27 Million ≈ $30.69 Million |
-- |
About Bioversys AG
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S.… Read more